The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 53, Issue 7, 2014, Pages 1344-1346

  Malaviya, Anshuman P ^a   Ledingham, Jo ^b   Bloxham, Jill ^c   Bosworth, Aisla ^d   Buch, Maya ^e   Choy, Ernest ^f   Cope, Andrew ^g   Isaacs, John ^h   Marshall, David ⁱ   Wright, Gary ^j   Östör, Andrew J K ^c  

^a BROOMFIELD HOSPITAL   (United Kingdom)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d NATIONAL RHEUMATOID ARTHRITIS SOCIETY   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

ⁱ INVERCLYDE ROYAL HOSPITAL   (United Kingdom)

^j ROYAL VICTORIA HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLUENZA VACCINE; LIPID; METHOTREXATE; PNEUMOCOCCUS VACCINE; TOCILIZUMAB;

ALCOHOL CONSUMPTION; ARTICLE; BREAST FEEDING; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIGESTIVE SYSTEM PERFORATION; DRUG SAFETY; GENERAL PRACTITIONER; HUMAN; INFLUENZA VACCINATION; JOINT PROSTHESIS; LIVER FUNCTION TEST; LIVER TOXICITY; NEUTROPENIA; NURSE; PARAMEDICAL PROFESSION; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SECONDARY HEALTH CARE;

ADMINISTRATION, INTRAVENOUS; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; HUMANS; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME;

EID: 84902984428     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu168     Document Type: Article

References (6)

1. Tocilizumab (RoActemra) Summary of Product Characteristics. http: //www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/ human/000955/WC500054890.pdf (16 April 2014, date last accessed).
2. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010; 7: CD008331.
3. National Institute for Health and Clinical Excellence. Tocilizumab for the Treatment of Rheumatoid Arthritis. TA 198. London: National Institute for Health and Clinical Excellence, 2010.
4. National Institute for Health and Clinical Excellence. Tocilizumab for the Treatment of Rheumatoid Arthritis (Rapid Review of Technology Appraisal Guidance 198). TA 247. London: National Institute for Health and Clinical Excellence, 2011.
5. Smolen JS, Schoels MM, Nishimoto N et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013; 72: 482-92.
6. Schoels MM, van der Heijde D, Breedveld FC et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 2013; 72: 583-9.